Results 121 to 130 of about 13,786,958 (257)

Comparison of outcomes after DA‐EPOCH‐R or GMALL high‐intensity therapy for front‐line treatment of Burkitt lymphoma: A retrospective cohort

British Journal of Haematology, EarlyView.
In this retrospective cohort of adult Burkitt lymphoma, DA‐EPOCH‐R showed no signal of inferior survival or relapse risk compared with GMALL‐based high‐intensity therapy. Outcomes were driven mainly by established prognostic factors, particularly age, advanced stage and Burkitt lymphoma International Prognostic Index.
Eduard Schulz, Florian Posch, Kristina Friedrich, Peter Neumeister, Katharina T. Prochazka   +4 more
wiley   +1 more source

Estudo da associação de genes e proteínas de resistência a múltiplos fármacos (abcb1/ABCB1, abcc1/ABCC1 e lrp/LRP) com marcadores moleculares em pacientes portadores de leucemias agudas [PDF]

, 2013
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação em Farmácia, Florianópolis, 2013.Menos de 45% dos portadores de leucemias agudas (LAs) sobrevivem cinco anos após o diagnóstico. O insucesso
Moraes, Ana Carolina Rabello de
core  

Galectin-3 in pre-B acute lymphoblastic leukemia

, 2013
Only 30-40% of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term, disease-free survival and can be considered cured. The remainder will eventually relapse and die from disease progression or other ALL-related consequences.
Lim, M, von Itzstein, M, von Itzstein, Mark, Heisterkamp, N., Arutyunyan, A, Heisterkamp, N, Fei, F., Groffen, J, Abdel-Azim, H, Arutyunyan, A., Groffen, J., Fei, F, Abdel-Azim, H., Lim, M.   +13 more
core   +1 more source

Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests

British Journal of Haematology, EarlyView.
Summary Haematological malignancies are rare in primary care and are hard to predict. Existing prediction models often require a specific working diagnosis and are based on extensive clinical information, access to which may be limited at initial work‐up in primary care.
Mathilde Egelund Christensen, Michael Charles Sachs, William Grant Dunn, Gustav Jonzon, Margit Kriegbaum, Bent Struer Lind, Jan Samuelsson, Kirsten Groenbaek, George Vassiliou, Christen Lykkegaard Andersen   +9 more
wiley   +1 more source

Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis [PDF]

, 2008
AML1/RUNX1 is a critical transcription factor in hematopoietic cell differentiation and proliferation. From the _AML1_ gene, at least three isoforms, _AML1a_, _AML1b_ and _AML1c_, are produced through alternative splicing.
Zhen Tian, Haiyan Xing, Xiangrong Liu, Dong-er Zhang, Min Wang, Qing Zhang, Qing Rao, Jianxiang Wang, Chunlin Zhou   +8 more
core  

Reduced‐dose versus standard‐dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Summary Comparative data on reduced‐dose (8 Gy) versus standard‐dose (12 Gy) total body irradiation (TBI) before allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for adults with acute lymphoblastic leukaemia (ALL) remain limited. We retrospectively analysed 101 adults undergoing first allo‐HSCT between 1999 and 2024 after 8 Gy or 12 Gy ...
Isabella Gruber, Matthias Edinger, Hendrik Poeck, Elisabeth Meedt, Ernst Holler, Wolfgang Herr, Oliver Koelbl, Daniel Wolff   +7 more
wiley   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib- based chemotherapy

, 2015
Junmei Zhao,* Chao Wang,* Yongping Song, Yuzhang Liu, Baijun FangHenan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital, Zhengzhou University, Zhengzhou, People’s Republic of China  *These authors ...
Liu Y, Wang C, Fang B, Zhao J, Song Y
core  

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source